FI970298L - DHA:n käyttö farmaseuttisena koostumuksena - Google Patents

DHA:n käyttö farmaseuttisena koostumuksena Download PDF

Info

Publication number
FI970298L
FI970298L FI970298A FI970298A FI970298L FI 970298 L FI970298 L FI 970298L FI 970298 A FI970298 A FI 970298A FI 970298 A FI970298 A FI 970298A FI 970298 L FI970298 L FI 970298L
Authority
FI
Finland
Prior art keywords
dha
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
FI970298A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI970298A0 (fi
FI970298A7 (fi
Inventor
Barbara Jacqueline Stordy
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of FI970298A0 publication Critical patent/FI970298A0/fi
Publication of FI970298A7 publication Critical patent/FI970298A7/fi
Publication of FI970298L publication Critical patent/FI970298L/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI970298A 1995-05-25 1996-05-24 DHA:n käyttö farmaseuttisena koostumuksena FI970298L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9510636.5A GB9510636D0 (en) 1995-05-25 1995-05-25 Fatty acid treatment
PCT/GB1996/001265 WO1996037200A1 (en) 1995-05-25 1996-05-24 Use of dha as a pharmaceutical composition

Publications (3)

Publication Number Publication Date
FI970298A0 FI970298A0 (fi) 1997-01-24
FI970298A7 FI970298A7 (fi) 1997-01-24
FI970298L true FI970298L (fi) 1997-01-24

Family

ID=10775045

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970298A FI970298L (fi) 1995-05-25 1996-05-24 DHA:n käyttö farmaseuttisena koostumuksena

Country Status (16)

Country Link
US (1) US6150411A (de)
EP (1) EP0774962B1 (de)
JP (1) JPH10503531A (de)
KR (1) KR970704433A (de)
AT (1) ATE264676T1 (de)
AU (1) AU722474B2 (de)
CA (1) CA2195979A1 (de)
DE (1) DE69632236T2 (de)
DK (1) DK0774962T3 (de)
ES (1) ES2217317T3 (de)
FI (1) FI970298L (de)
GB (1) GB9510636D0 (de)
NO (1) NO970317L (de)
PT (1) PT774962E (de)
WO (1) WO1996037200A1 (de)
ZA (1) ZA964215B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE361066T1 (de) * 1998-10-15 2007-05-15 Dsm Ip Assets Bv Polyungesättigen fettsäuren nährungsergänzung
KR100341109B1 (ko) * 1999-03-10 2002-06-20 이인수 인식력 및 기억력 증강용 식이 조성물
US7112609B2 (en) * 1999-06-01 2006-09-26 Drugtech Corporation Nutritional supplements
US6258846B1 (en) * 1999-06-01 2001-07-10 Drugtech Corporation Nutritional supplements
GB9918023D0 (en) 1999-07-30 1999-09-29 Unilever Plc Skin care composition
US6479545B1 (en) 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
DK1417211T3 (da) 2001-07-27 2007-10-08 Neptune Technologies & Bioress Naturlige phospholipider af marin oprindelse, der indeholder flavonoider og polyumættede phospholipider, og deres anvendelse
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
TWI365716B (en) * 2003-12-02 2012-06-11 Suntory Holdings Ltd Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same
EP1713463A4 (de) * 2004-01-19 2009-03-18 Martek Biosciences Corp Reelin-mangel oder dysfunktion und relevante verfahren
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US20070166411A1 (en) * 2005-12-16 2007-07-19 Bristol-Myers Squibb Company Nutritional supplement containing long-chain polyunsaturated fatty acids
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0813599D0 (en) * 2008-07-24 2008-09-03 Pharma Marine As Method
WO2011050474A1 (en) 2009-10-29 2011-05-05 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
CA3024191C (en) * 2016-06-01 2024-05-28 Nestec S.A. Composition for use in the prophylaxis of allergic disease
EP4440564A4 (de) * 2021-12-02 2026-03-11 Univ California Zusammensetzungen und verfahren zur hemmung von anfällen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
EP0711503A3 (de) * 1994-11-14 1997-11-26 Scotia Holdings Plc Mit GLA und/oder DGLA angereicherte Milch

Also Published As

Publication number Publication date
HK1012575A1 (en) 1999-08-06
FI970298A0 (fi) 1997-01-24
JPH10503531A (ja) 1998-03-31
EP0774962A1 (de) 1997-05-28
KR970704433A (ko) 1997-09-06
AU722474B2 (en) 2000-08-03
EP0774962B1 (de) 2004-04-21
DE69632236T2 (de) 2005-04-14
AU5827796A (en) 1996-12-11
PT774962E (pt) 2004-09-30
DK0774962T3 (da) 2004-08-09
ZA964215B (en) 1996-12-04
FI970298A7 (fi) 1997-01-24
DE69632236D1 (de) 2004-05-27
ES2217317T3 (es) 2004-11-01
US6150411A (en) 2000-11-21
GB9510636D0 (en) 1995-07-19
CA2195979A1 (en) 1996-11-28
WO1996037200A1 (en) 1996-11-28
ATE264676T1 (de) 2004-05-15
NO970317D0 (no) 1997-01-24
NO970317L (no) 1997-01-24

Similar Documents

Publication Publication Date Title
FI970298L (fi) DHA:n käyttö farmaseuttisena koostumuksena
NO962606D0 (no) Farmasöytisk sammensetning
CY2005007I2 (el) Φαρμακευτικες συνθεσεις που περιεχουν δαριφενακινη
IS4706A (is) Lyfjasamsetningar
ATE284695T1 (de) Oral anzuwendende arzneizusammensetzung enthaltend 2-methyl-thienobenzodiazepin
FI955144L (fi) Päällystetyt farmaseuttiset koostumukset
FI944832A0 (fi) Farmaseuttinen koostumus
BR9610396A (pt) Formulação farmacêutica
ITMI932540A0 (it) Composizione farmaceutica
DE69614407D1 (de) Pharmazeutische zusammensetzungen
BR9507768A (pt) Composição farmacêutica
LV11727A (lv) Farmaceitiska kompozicija
FI973229A0 (fi) Uusi farmaseuttinen koostumus
FI943705L (fi) Farmaseuttiset koostumukset
FI973280A0 (fi) Farmaseuttinen koostumus
FI973230A7 (fi) Uusi farmaseuttinen formulaatio
FI940726A7 (fi) Farmaseuttiset koostumukset
LV10579A (lv) Farmaceitiska kompozicija
FI934387A0 (fi) 3-substituerade 2-oxi-indol-1-karboxiamid omfattande farmaceutiska kompositioner
BR9605777A (pt) Composição farmacêutica
NO964309D0 (no) Farmasöytisk sammensetning
IT1272935B (it) Composizione farmaceutica contenente n-acetil-cisteina
SE9402924D0 (sv) Novel pharmaceutical composition
ATE239508T1 (de) Partikulare arzneiform
BR1100200A (pt) Composição farmacêutica